^
    Back
    Association details:
    Biomarker:MLL rearrangement
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:MK-2206 (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    DGHO 2020
    Title:

    Pan-AKT inhibitor MK-2206 demonstrates anti-leukemic potential in MLL-rearranged BCP-ALL cell lines and primary samples

    Published date:
    10/09/2020
    Excerpt:
    MLLr cell lines SEM and RS4;11 displayed fragmented nuclei and an increased amount of cellular debris while REH and NALM-6 cells shrinked clearly.The pan-AKT inhibitor MK demonstrates significant anti leukemic potential in BCP-ALL cells of different genetic background.